BioXcel Therapeutics, Inc.

What they do

BioXcel uses a proprietary AI platform to identify new indications for existing or clinically evaluated drugs. Its lead neuroscience candidate BXCL501 is an orally dissolving sublingual film of dexmedetomidine, approved by the FDA in April 2022 as IGALMI for acute agitation in schizophrenia or bipolar I/II disorder under healthcare supervision. The wholly owned subsidiary OnkosXcel develops BXCL701, an oral innate immune activator for aggressive prostate and pancreatic cancers, though that program is deprioritized.

Revenue drivers

• IGALMI (dexmedetomidine) sublingual film — The only FDA-approved product, sold in 120 mcg and 180 mcg doses for acute agitation in schizophrenia or bipolar disorder; net revenue was $642,000 for full-year 2025, with quarterly revenue between $98,000 and $256,000 over the last four reported quarters.
• At-home label expansion for IGALMI — Not yet revenue-generating; the sNDA filed January 14, 2026 seeks approval for at-home use in acute agitation in bipolar disorder and schizophrenia, with a PDUFA target action date of November 14, 2026. The company has said approval would represent the first FDA-approved at-home treatment option for acute agitation in these conditions.
• BXCL501 Alzheimer's agitation program (TRANQUILITY) — Pre-revenue; a planned second TRANQUILITY In-Care Phase 3 trial would evaluate a 60 mcg dose of BXCL501 for agitation associated with Alzheimer's dementia, but the company states it is advancing plans for initiation upon funding.
• OnkosXcel BXCL701 immuno-oncology — Pre-revenue; the BXCL701 programs for prostate and pancreatic cancer continue to be deprioritized, so this segment currently contributes no reported revenue.

Recent performance

Second-quarter 2026 revenue was $182,000, down from $206,000 in first-quarter 2026 and $256,000 in fourth-quarter 2025. Full-year 2025 revenue was $642,000, compared with $2.3 million in 2024 and $1.4 million in 2023. The net loss was $69.9 million in 2025 and $59.6 million in 2024; operating cash use was $57.6 million in 2025 and $72.0 million in 2024. First-quarter 2026 R&D expense fell to $3.0 million from $4.6 million a year earlier, primarily due to completion of the SERENITY At-Home pivotal Phase 3 safety trial, while cost of goods sold rose to $283,000 from $14,000 on higher excess or obsolete inventory reserves. As of June 30, 2026, total assets were $28.8 million, total liabilities were $144.3 million, and shareholders' equity was negative $115.5 million.

Strategy

Management has engaged MTS Health Partners to evaluate strategic options including a sale of the company, merger or business combination, collaboration, joint venture, royalty or license agreement, recapitalization, other financing, or continued standalone execution. Commercially, the company is preparing a launch plan for IGALMI in the at-home setting and maintaining brand awareness with minimal commercial resources. Development priorities are the SERENITY at-home label expansion and the TRANQUILITY program in Alzheimer's dementia, which is planned for initiation upon funding. The BXCL701 immuno-oncology programs remain deprioritized. Under the Twelfth Amendment to its Credit Agreement, the company was required, on or prior to August 21, 2026, to enter into definitive agreements for a transaction acceptable to Lenders that would repay all obligations or constitute an acceptable alternative capital solutions transaction.

Risks

• Going-concern and liquidity — With $28.8 million in cash, cash equivalents and restricted cash at December 31, 2025 and no current availability under its funding facilities, the company stated it does not believe it has sufficient cash to support operations and service debt for at least one year, raising substantial doubt about its ability to continue as a going concern.
• Credit agreement and lender deadlines — The Credit Agreement requires delivery of audited annual financial statements without a going-concern qualification and, under the Twelfth Amendment, required definitive agreements by August 21, 2026 to repay all obligations or complete an acceptable alternative capital transaction; strategic alternatives also require Lender consent.
• Possible bankruptcy — Management has stated that if it cannot continue as a viable entity it may be required to seek relief under the U.S. Bankruptcy Code, with no guarantee it would emerge as a going concern or that common stockholders would receive any recovery.
• Dependence on one approved product and a pending sNDA — IGALMI is the only revenue-generating product, with full-year 2025 revenue of $642,000 and quarterly revenue below $260,000, so results depend heavily on the FDA's November 14, 2026 decision on the at-home sNDA.

Outlook

Management points to the FDA's acceptance of the IGALMI at-home sNDA with a PDUFA target action date of November 14, 2026, and is preparing a commercial launch plan for that setting while maintaining IGALMI brand awareness with minimal commercial resources. It says the TRANQUILITY In-Care Phase 3 trial of a 60 mcg dose of BXCL501 for Alzheimer's dementia is planned for initiation upon funding. The company continues to evaluate strategic options with MTS Health Partners and has set no timetable for completion or assurance that any transaction will result. BXCL701 development remains deprioritized.